Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; mannitol; methionine; microcrystalline cellulose; povidone; magnesium stearate; sodium carbonate; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of nonfatal myocardial infarction and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; sodium carbonate; methionine; povidone; mannitol; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of nonfatal myocardial infarction and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; sodium carbonate; purified talc; povidone; methionine; microcrystalline cellulose; crospovidone; mannitol; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; crospovidone; sodium carbonate; magnesium stearate; mannitol; methionine; titanium dioxide; hypromellose; macrogol 6000 - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia.,prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated.,hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of nonfatal myocardial infarction and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: sodium carbonate; povidone; magnesium stearate; crospovidone; purified talc; mannitol; microcrystalline cellulose; methionine; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; methionine; mannitol; microcrystalline cellulose; purified talc; sodium carbonate; povidone; titanium dioxide; hypromellose; macrogol 6000 - an adjunct to diet for the treatment of patients with hypercholesterolaemia. . prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; colloidal anhydrous silica; butylated hydroxytoluene; microcrystalline cellulose; croscarmellose sodium; sodium carbonate; magnesium stearate; butylated hydroxyanisole; hyprolose; lactose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: sodium lauryl sulfate; butylated hydroxytoluene; lactose; colloidal anhydrous silica; hyprolose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; butylated hydroxyanisole; sodium carbonate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: sodium carbonate; microcrystalline cellulose; lactose; butylated hydroxytoluene; butylated hydroxyanisole; sodium lauryl sulfate; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; hyprolose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - atorvastatin calcium, quantity: 10.36 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; lactose; hyprolose; sodium lauryl sulfate; croscarmellose sodium; microcrystalline cellulose; butylated hydroxyanisole; sodium carbonate; butylated hydroxytoluene; magnesium stearate; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.